By: IPP Bureau
Last updated : August 09, 2025 9:27 pm
Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter ended 30th June 2025.
PAT for Q1 FY26 stood at Rs. 9.1 crore as compared to Rs. 7.6 crore, reflecting a growth of 19.67% year-on-year. The PAT margin for Q1 FY26 was 12.64%.
For Q1 FY26, the company reported total income of Rs. 73.4 crore as compared to Rs. 61.8 crore, reflecting a growth of 18.83%.
EBITDA for Q1 FY26 reached Rs. 24.65 crore, marking a 13.51% increase from Q1 FY25. The EBITDA margin for Q1 FY26 stood at 33.97%.
The company launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and molecular testing services. This state-of-the-art facility brings comprehensive capabilities across key domains, including prenatal diagnostics (QF-PCR, Karyotyping, FISH, Microarray, and NIPT), identification of inherited disorders (such as single-gene mutation analysis and whole exome sequencing), pharmacogenomics, and specialized oncology panels.
The company also acquired 63% stake in Fetomat Wellness Private Limited (‘Fetomat’) on 09th April 2025. Fetomat, a specialized healthcare provider focused on pregnancy care, women’s ultrasound scanning, prenatal diagnostics, genetic counselling, and medical training for doctors, marks a strategic addition to our portfolio. We believe this acquisition creates strong synergies with our existing operations and unlocks new opportunities for sustainable growth in the healthcare segment.
Commenting on the results, Ritu Mittal, Joint Managing Director & CEO said,: “We are pleased to report a strong performance for Q1 FY26, driven by consistent growth across our operations. In the quarter we have also marked major milestone with the launch of Suraksha Genomics, this new vertical, equipped with state-of-the-art high-throughput sequencing platforms, positions us at the forefront of precision medicine in Eastern India.
Our strategic focus remains ambitious and future-ready. We are actively expanding into whole genome and metagenomic testing, while integrating AI-assisted variant interpretation to elevate diagnostic accuracy.
Additionally, we are laying the groundwork for population-scale genomic screening programs, an initiative that holds transformative potential for public health. Clinical partnerships continue to be a cornerstone of our approach, enabling us to translate scientific advancements into meaningful improvements in patient care and research outcomes.
As newer centres stabilize and begin contributing significantly, we expect to see a stronger and more profitable financial profile across our network. We remain committed to innovation, operational excellence, and sustainable growth as we advance our mission to redefine healthcare delivery through genomics.”